Antibody production and characterization
Ended Awarded Last action
- Contract number
- 75N91018F00064
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,418,352
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $5,418,352.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,164,546 | |
| Exercise an Option | $2,176,347 | |
| Original award | $1,077,459 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 24, 2018, under a cost-plus-fixed-fee structure with a ceiling value of $5.4 million for antibody production and characterization, with an ultimate completion date of September 23, 2023. Place of performance is Frederick, MD.
Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute and National Institutes of Health, delivering biomedical research and facilities support services. The order carried no set-aside designation.
Service Contract Inventory reporting reflects declining labor intensity and government-paid rates across the order's life. In FY2023, the most recent reported period, the order invoiced $1.1 million across 4.1 FTEs and 8,458 contractor hours at a derived blended rate of $129.56 per hour. FY2022 represented peak volume at $2 million invoiced and 6.7 FTEs. Subcontractor utilization grew substantially, with 99 percent of FY2023 contractor hours performed by three subcontractors, compared to lower subcontracting in prior years.
Quick answers
Who was awarded contract 75N91018F00064?
75N91018F00064 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2018.
How much is contract 75N91018F00064 worth?
The government has obligated $5,418,352 on 75N91018F00064.
Is contract 75N91018F00064 an order under another contract?
Yes. 75N91018F00064 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00064 competed?
The extent of competition for 75N91018F00064 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award